Statins and Myasthenia Gravis: Clinical Implications and Pathogenesis

Abstract

Statins are widely prescribed lipid-lowering agents and remain central to the prevention of atherosclerotic cardiovascular disease. Although generally well tolerated, they have been associated with neuromuscular adverse events, including new-onset or worsening myasthenia gravis (MG).

The paper